Home Tags Multi-pass transmembrane protein

Tag: multi-pass transmembrane protein

BioRay’s IND Application for BRY812, Accepted by the China National Medical...

ADC Review | Editorial Team
The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors (Acceptance No. CXSL2300366).  The investigational drug is being developed by Shanghai-based BioRay Pharmaceutical Co.